{
    "nctId": "NCT03961880",
    "briefTitle": "Impact of Recurrence Score on Adjuvant Treatment Decisions in Breast Cancer Patients",
    "officialTitle": "Impact of Recurrence Score on Adjuvant Treatment Decisions and Tumor Cell Dissemination in Estrogen-receptor Positive and HER2 Negative Patients With Early Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer Female",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 250,
    "primaryOutcomeMeasure": "Evaluation of the influence of the 21-gene Recurrence-Score (RS) on adjuvant therapy recommendation",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* women \u2265 18 years of age\n* histologically proven unilateral primary non-metastatic invasive breast cancer\n* ER-/ or PR- positive and HER2-negative\n* N0-N1 (0-3 involved lymph-nodes). The nodal status may be evaluated clinically.\n* surgery or planed surgery at the Department of women's health, Tuebingen\n* written informed consent into IRMA\n\nExclusion Criteria:\n\n* ER-negative\n* HER2-positive\n* \\> 3 involved lymph-nodes\n* bilateral breast cancer\n* preexisting cancer disease within the last 10 years\n* preexisting invasive ipsi- or contralateral breast cancer (non-invasive ipsi- or contralateral breast cancer is not regarded as an exclusion criteria)\n* primary systemic therapy\n* locally advanced, inoperable or metastatic breast cancer\n* pregnant or lactating patients\n* inadequate general condition (not fit for chemotherapy)",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}